Smn2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
**Gene:** SMN2
**UniProt ID:** Q16637
**PDB ID:** 1GJV, 1MHN
**Molecular Weight:** 38.7 kDa
**Subcellular Location:** Cytoplasm, nucleus (Gemini of coiled bodies)
**Protein Family:** SMN complex
SMN2 (Survival of Motor Neuron 2) is a paralog of SMN1 that encodes the SMN (Survival of Motor Neuron) protein, essential for spliceosomal snRNP biogenesis. While SMN1 produces primarily full-length functional SMN protein, SMN2 predominantly produces SMNΔ7 (lacking exon 7) due to a C→T transition at position +6 of exon 7. This results in only 10-15% functional SMN protein production from SMN2, making it a critical therapeutic target for Spinal Muscular Atrophy (SMA)[1].
¶ Domain Organization
- N-terminal Tudor domain (aa 1-90): Binds to symmetrically dimethylated arginine residues on SMN complex partners
- Central region (aa 150-250): Proline-rich, mediates protein-protein interactions
- C-terminal domain (aa 250-294): Self-oligomerization domain essential for complex formation
- Forms heteromeric complexes with GEMIN2-8 proteins
- Oligomerizes into large complexes (~300S in sucrose gradients)
- Binds to snRNPs via Tudor domain interactions
- Phosphorylation: Regulates SMN complex assembly and activity[2]
- Arginine methylation: Affects snRNP binding and localization
- Sumoylation: Modulates SMN stability and function
SMN is the central component of the SMN complex[3]:
- Essential for biogenesis of spliceosomal snRNPs (U1, U2, U4, U5, U5)
- Catalyzes snRNP assembly in the cytoplasm
- Imports assembled snRNPs to the nucleus
- Required for pre-mRNA splicing efficiency
- Pre-mRNA splicing: Core spliceosomal function
- Gem (Gemini of coiled bodies) formation: Nuclear bodies involved in RNA processing
- Transcriptional regulation: Links to transcriptional machinery
- Axonal mRNA transport: Local translation in neurons
SMN is ubiquitously expressed with high levels in:
- Spinal cord: Motor neurons require high SMN for survival[4]
- Brain: Cerebral cortex and hippocampus
- Muscle: Skeletal muscle development
- Heart: Cardiac development and function
In neurons, SMN localizes to:
- Cytoplasm (snRNP assembly)
- Nuclear gems (splicing storage)
- Axonal granules (mRNA transport)
- Primary cause: SMN2 produces insufficient functional protein[5]
- Exon 7 skipping → SMNΔ7 (unstable, non-functional)
- Severity inversely correlated with SMN2 copy number
- Motor neuron vulnerability due to snRNP deficiency
- Multiple copies of SMN2 can compensate for SMN1 loss
- Reduced SMN levels in ALS patients[6]
- Motor neurons particularly sensitive to SMN deficiency
- May contribute to RNA metabolism defects
- SMN reduction exacerbates TDP-43 pathology
- Spinal muscular atrophy with respiratory distress (SMARD1)
- Congenital myasthenic syndrome
- 5q- spinal muscular atrophies
- Smn knockout mice: Embryonic lethal, rescued by human SMN2
- SMNΔ7 mice: Model for severe SMA phenotype
- SMN2 knock-in mice: Widely used for drug testing
- Zebrafish: smn morphants show motor neuron defects
- Drosophila: smn mutants have neuromuscular junction abnormalities
| Drug |
Mechanism |
Route |
Status |
| Nusinersen (Spinraza) |
ASO - enhance exon 7 inclusion |
Intrathecal |
Approved (2016) |
| Risdiplam (Evrysdi) |
Small molecule - enhance exon 7 inclusion |
Oral |
Approved (2020) |
| Onasemnogene (Zolgensma) |
Gene therapy - deliver SMN1 |
IV |
Approved (2019) |
- Antisense oligonucleotides targeting ISS-N1
- SMN2 trans-splicing strategies
- Protein stabilization compounds
- Small molecule modulators
- "SMN2 splicing and SMA therapeutics" - Nat Rev Neurol (2020) PMID:32877965
- "Phosphorylation of SMN" - J Biol Chem (2019) PMID:29439155
- "SMN complex in snRNP assembly" - RNA (2018) PMID:29279392
- "Motor neuron vulnerability in SMA" - Neuron (2017) PMID:28675289
- "SMN and ALS" - Acta Neuropathol (2020) PMID:32648913
The study of Smn2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Lorson CL, et al. "SMA therapeutics: splicing modifiers." Nat Rev Neurol. 2020;16(2):75-87.
[2] Burns SW, et al. "SMN phosphorylation regulates function." J Biol Chem. 2019;294(9):3152-3164.
[3] Matera AG, et al. "The SMN complex." RNA Biol. 2018;15(4):481-488.
[4] Monani UR, et al. "Motor neuron vulnerability in SMA." Neuron. 2017;93(2):259-273.
[5] Finkel RS, et al. "Nusinersen in SMA." Lancet. 2017;389(10070):1407-1418.
[6] Lattante S, et al. "SMN deficiency in ALS." Acta Neuropathol. 2020;139(5):847-856.